We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Amchara Health specialises in bringing a better approach to creating a personalised health solution tailored to a person's needs and goals. Its aim is to educate and empower people about better health choices. This residential retreat brand is developing three health & wellness applications: HealthHub360, MyAmchara, and Amchara360. In the first 12 months, the company will aim to achieve more than 100,000 downloads of the Healthhub360 application. With the proceeds, Amchara will be marketing the MyAmchara app and rebrand it. Furthermore, there will be an international development of the application to cater to Canada, Australia, and the USA.
days to go: Expired investment: £167,619
Rabble is a gamified and licensed fitness program that transforms exercise into fun, team-based games. It was first formed by a former international athlete and then financed by investors from the LA Fitness & Liverpool football club. Rabble has quickly risen to 100 authorized sites strengthening many healthy communities over the UK. It is a differentiated concept which is named as Global Fitness Trend (WGSN). It has a proven and scalable model where the market leaders earn revenue of more than $100m. Further, it has developed 100+ instructors across the UK in less than one year. Rabble aims at helping and changing more lives with the finance that it raises. It is planning to grow to more than 300 Rabble sites in the coming year.
days to go: Expired investment: £274,530
Q Doctor aims at changing the NHS care delivery with the help of video consulting to benefit patients and clinicians. The company is focusing on delivering a model that keeps modernised NHS care free of charge for the patients. The video solution plugs NHS clinicians to the existing NHS infrastructure and allows them to connect to the NHS patients digitally. With the proceeds, Q Doctor will fulfil its strategy for 2020. It will deploy the funds into labour, development, operations, marketing, and contingency funds.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,386,200
TeaTime deliver fresh and healthy tea blends straight to your door. Simply choose how often you wish to receive your box, weekly or fortnightly and TeaTime will dispatch a selection of 4 of their blends out to you within 48 hours.
days to go: Expired investment: £18,940
The Cauldron is a technology-led entertainment studio that aims to deliver immersive experiences to its guests by combining technology with food and drink. Upon entering the company's venues, guests are given a magic wand, which acts as a control device for their visit. It helps them pour pints, activate lights and locks, explore science experiments, and stir cocktails. The device is also programmed to act as an open bar tab to track user spending. The Cauldron has served 1 million potions till date, welcomed 260,000+ guests and built a mailing list of over 72,000 subscribers. The company has featured in publications like Thrillist, NBC, Forbes, and Edinburgh News. The Cauldron will use 40% of the investment to open a central-London Cauldron flagship and provide additions to its Wands & Wizard Exploratorium, a new five-floor venue on Greek Street in the very heart of London’s Soho, 40% to grow its retail technology, and 20% to pay staff salaries.
days to go: Expired investment: £364,143
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph